Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Income from Continuing Operations (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Income from Continuing Operations for 13 consecutive years, with 3615000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 128.47% to 3615000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 29356000.0, a 160.49% increase, with the full-year FY2024 number at 56418000.0, down 8.53% from a year prior.
  • Income from Continuing Operations was 3615000.0 for Q3 2025 at Theravance Biopharma, down from 54806000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 114444000.0 in Q4 2022 to a low of 79679000.0 in Q1 2021.
  • A 5-year average of 12815529.41 and a median of 15221000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 91.0% in 2023, then soared 460.07% in 2025.
  • Theravance Biopharma's Income from Continuing Operations stood at 55744000.0 in 2021, then surged by 305.3% to 114444000.0 in 2022, then plummeted by 107.82% to 8950000.0 in 2023, then crashed by 73.49% to 15527000.0 in 2024, then skyrocketed by 123.28% to 3615000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Income from Continuing Operations are 3615000.0 (Q3 2025), 54806000.0 (Q2 2025), and 13538000.0 (Q1 2025).